Market Cap 2.37B
Revenue (ttm) 0.00
Net Income (ttm) -111.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 2.24
Volume 983,900
Avg Vol 1,510,290
Day's Range N/A - N/A
Shares Out 42.43M
Stochastic %K 55%
Beta 0.72
Analysts Strong Sell
Price Target $69.43

Company Profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 neg...

Industry: Biotechnology
Sector: Healthcare
Phone: (763) 392-0767
Address:
16305 36th Avenue North, Suite 100, Minneapolis, United States
kshonstocks
kshonstocks Sep. 10 at 10:22 PM
$CELC more good news after close Baker Bros adds abt 170K Celcuity shares worth c. $10 Million
0 · Reply
outlawinvestor1
outlawinvestor1 Sep. 10 at 8:25 PM
$CELC baker bros and CEO buying. 🤔
0 · Reply
PacBoiLar
PacBoiLar Sep. 8 at 5:55 PM
$CELC Seems like FDA review going pretty well. So refreshing to be able to take everything the executive team shares at face value. Triple digits by end of 2026
0 · Reply
Brownnotes
Brownnotes Sep. 8 at 4:10 PM
$CELC Schwab rejecting orders for this. Broker only trades... Called, said it's on FTC section 12 list.. Fidelity, no problem. What gives? Other than Schwab
2 · Reply
Jonita
Jonita Sep. 8 at 2:47 PM
$CELC in in in
1 · Reply
outlawinvestor1
outlawinvestor1 Sep. 8 at 10:12 AM
$CELC $RAPP https://investors.rapportrx.com/news-releases/news-release-details/rapport-announces-positive-topline-results-phase-2a-clinical
0 · Reply
Camtanren
Camtanren Sep. 7 at 1:30 PM
$CELC isn’t there another readout coming soon ?
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Sep. 7 at 2:32 AM
Just for fun, the attachment lists the top 25 one-day gains in bio stocks YTD. Gains ranged from 105 to 788%. It shows the changes 1 week later, 4 weeks later & through last Friday's close 9/5/25. Roughly 2 of every 3 stocks fell the following week after the big gain, 4 weeks later & through last Friday. The higher the market cap the day before the big gain the lower the risk of future losses. $CRVO & $QNTM share prices hung in there despite the low market cap (versus their peers) though QNTM has been steadily heading lower lately. $ABVX $CELC & $CDTX clearly bucked the trend versus their peers. We focus on commercial-stage bio so no disrespect. We do not follow any of the 3. DRRX is excluded because its gain was due to M&A Again this post is just for fun. It is possible This is not investment advice.
0 · Reply
outlawinvestor1
outlawinvestor1 Sep. 4 at 8:30 PM
$CELC CEO exercising warrant purchase w/out a sale is very bullish imho.
0 · Reply
kshonstocks
kshonstocks Sep. 2 at 4:20 PM
$ABVX $CELC impressive in the slopfest
0 · Reply
Latest News on CELC
Celcuity Inc. (CELC) Q2 2025 Earnings Call Transcript

Aug 15, 2025, 11:40 AM EDT - 27 days ago

Celcuity Inc. (CELC) Q2 2025 Earnings Call Transcript


Celcuity: What's Happening With CELC Stock?

Jul 29, 2025, 6:40 AM EDT - 6 weeks ago

Celcuity: What's Happening With CELC Stock?


Celcuity Inc. (CELC) Q1 2025 Earnings Call Transcript

May 14, 2025, 9:36 PM EDT - 4 months ago

Celcuity Inc. (CELC) Q1 2025 Earnings Call Transcript


Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 10:50 PM EDT - 5 months ago

Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript


Celcuity's High-Stakes Oncology Bet Is Underappreciated

Feb 19, 2025, 6:24 PM EST - 7 months ago

Celcuity's High-Stakes Oncology Bet Is Underappreciated


Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 7:42 PM EST - 10 months ago

Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript


Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript

Aug 16, 2024, 3:50 PM EDT - 1 year ago

Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript


Celcuity: Flying A Phase 3 Trial Right Under Your Nose

Jul 5, 2024, 12:05 AM EDT - 1 year ago

Celcuity: Flying A Phase 3 Trial Right Under Your Nose


Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript

May 15, 2024, 7:43 PM EDT - 1 year ago

Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript


Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 6:40 PM EDT - 1 year ago

Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript


Celcuity Appoints Eldon Mayer as Chief Commercial Officer

Feb 20, 2024, 7:05 AM EST - 1 year ago

Celcuity Appoints Eldon Mayer as Chief Commercial Officer


kshonstocks
kshonstocks Sep. 10 at 10:22 PM
$CELC more good news after close Baker Bros adds abt 170K Celcuity shares worth c. $10 Million
0 · Reply
outlawinvestor1
outlawinvestor1 Sep. 10 at 8:25 PM
$CELC baker bros and CEO buying. 🤔
0 · Reply
PacBoiLar
PacBoiLar Sep. 8 at 5:55 PM
$CELC Seems like FDA review going pretty well. So refreshing to be able to take everything the executive team shares at face value. Triple digits by end of 2026
0 · Reply
Brownnotes
Brownnotes Sep. 8 at 4:10 PM
$CELC Schwab rejecting orders for this. Broker only trades... Called, said it's on FTC section 12 list.. Fidelity, no problem. What gives? Other than Schwab
2 · Reply
Jonita
Jonita Sep. 8 at 2:47 PM
$CELC in in in
1 · Reply
outlawinvestor1
outlawinvestor1 Sep. 8 at 10:12 AM
$CELC $RAPP https://investors.rapportrx.com/news-releases/news-release-details/rapport-announces-positive-topline-results-phase-2a-clinical
0 · Reply
Camtanren
Camtanren Sep. 7 at 1:30 PM
$CELC isn’t there another readout coming soon ?
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Sep. 7 at 2:32 AM
Just for fun, the attachment lists the top 25 one-day gains in bio stocks YTD. Gains ranged from 105 to 788%. It shows the changes 1 week later, 4 weeks later & through last Friday's close 9/5/25. Roughly 2 of every 3 stocks fell the following week after the big gain, 4 weeks later & through last Friday. The higher the market cap the day before the big gain the lower the risk of future losses. $CRVO & $QNTM share prices hung in there despite the low market cap (versus their peers) though QNTM has been steadily heading lower lately. $ABVX $CELC & $CDTX clearly bucked the trend versus their peers. We focus on commercial-stage bio so no disrespect. We do not follow any of the 3. DRRX is excluded because its gain was due to M&A Again this post is just for fun. It is possible This is not investment advice.
0 · Reply
outlawinvestor1
outlawinvestor1 Sep. 4 at 8:30 PM
$CELC CEO exercising warrant purchase w/out a sale is very bullish imho.
0 · Reply
kshonstocks
kshonstocks Sep. 2 at 4:20 PM
$ABVX $CELC impressive in the slopfest
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 28 at 12:18 PM
$CELC (+7.7% pre) Celcuity Stock Soars on FDA Approval News https://ooc.bz/l/75474
1 · Reply
BIOTECH_GURU
BIOTECH_GURU Aug. 28 at 12:37 AM
$CELC still room to run.
0 · Reply
topstockalerts
topstockalerts Aug. 28 at 12:25 AM
After Hours Top Gainers PT2 $ICCM $FGNX $KTTA $AGFY $CELC
0 · Reply
Florestan
Florestan Aug. 27 at 10:55 PM
$CELC Bears are gonna rope themselves lol.
0 · Reply
kshonstocks
kshonstocks Aug. 27 at 10:25 PM
Great news for $CELC Not expected this soon
0 · Reply
PacBoiLar
PacBoiLar Aug. 27 at 9:51 PM
$CELC can’t wait to see how this plays out https://ir.celcuity.com/press-releases/
1 · Reply
ChartElite
ChartElite Aug. 27 at 6:47 AM
$CELC is catching buzz as traders revisit the biotech’s platform for extracellular matrix therapeutics and hope for a turnaround after recent volatility.
1 · Reply
Paxhawig
Paxhawig Aug. 27 at 5:56 AM
$BTAI $CELC Bad comparison. Btai is non compliant and penny stock.
1 · Reply
Osc1973
Osc1973 Aug. 27 at 5:52 AM
$BTAI $CELC I second this my fellow bulls
0 · Reply
UpcomingCatalyst
UpcomingCatalyst Aug. 27 at 5:34 AM
$BTAI Not all Phase 3 positive results are created equal. Just look at $CELC—after its positive Phase 3 readout, the stock surged over 300% in a single move. The key is understanding what kind of Phase 3 trial we’re talking about. In this case, there is no FDA-approved at-home treatment available for this critical indication. That means the market opportunity is enormous—driven by massive unmet demand, life-saving potential, and the possibility of establishing the first-ever standard of care in the home setting. This isn’t just another biotech readout. It’s a chance at unlocking a multi-billion-dollar market opportunity. The stakes, and the upside, coudn't be higher !!
4 · Reply
PacBoiLar
PacBoiLar Aug. 27 at 12:13 AM
$CELC stock is trading at 50.50 in after hours, but I think it’s a better chance than 50/50 that this is over $100 by end of 2026
0 · Reply
Makememillionaire
Makememillionaire Aug. 26 at 8:14 PM
$BTAI $CELC did the same. The data will be released before the conference call. Good luck traders
1 · Reply